Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CYSLTR1 [1] Neuroactive ligand-receptor interaction D01385 Ibudilast [2] 2, 13
2 CYSLTR1 [1] Neuroactive ligand-receptor interaction D06659 Tipelukast [1] 85
3 CYSLTR1 [1] Neuroactive ligand-receptor interaction D08229 Montelukast [8] 6, 13, 46, 61, 63, 85, 98, 228
4 HRH3 [1] Neuroactive ligand-receptor interaction D09870 Bavisant [1] 6
5 HRH3 [1] Neuroactive ligand-receptor interaction D10749 Pitolisant [3] 6, 113, 193
6 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
7 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
8 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
9 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [1] 6
10 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
11 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
12 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
13 CHRM1 [4] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
14 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00113 Atropine [2] 2, 299
15 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00138 Scopolamine [1] 2
16 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00270 Chlorpromazine [1] 254
17 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00397 Tropicamide [1] 6
18 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
19 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D00525 Pilocarpine [3] 6, 53, 299
20 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D07226 Fesoterodine [1] 6
21 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D08441 Propiverine [1] 226
22 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
23 CHRM2 [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton D11383 Blarcamesine [1] 156
24 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
25 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
26 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
27 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [1] 6
28 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
29 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00525 Pilocarpine [3] 6, 53, 299
30 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D00646 Tolterodine [2] 17, 53
31 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D03654 Darifenacin [2] 6, 13
32 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D07226 Fesoterodine [1] 6
33 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D07667 Cevimeline [1] 53
34 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
35 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08522 Solifenacin [3] 6, 13, 53
36 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
37 CHRM3 [6] Neuroactive ligand-receptor interaction, Taste transduction, Regulation of actin cytoskeleton, Salivary secretion, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
38 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00113 Atropine [2] 2, 299
39 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00138 Scopolamine [1] 2
40 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00270 Chlorpromazine [1] 254
41 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00397 Tropicamide [1] 6
42 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D00465 Oxybutynin [3] 6, 13, 53
43 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D08441 Propiverine [1] 226
44 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D08638 Trihexyphenidyl [2] 5, 6
45 CHRM4 [2] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton D11383 Blarcamesine [1] 156
46 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00113 Atropine [2] 2, 299
47 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00138 Scopolamine [1] 2
48 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00270 Chlorpromazine [1] 254
49 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide [1] 6
50 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin [3] 6, 13, 53
51 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226
52 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D08638 Trihexyphenidyl [2] 5, 6
53 CHRM5 [3] Neuroactive ligand-receptor interaction, Regulation of actin cytoskeleton, Pathways of neurodegeneration - multiple diseases D11383 Blarcamesine [1] 156
54 CHRNA1 [2] Virion - Lyssavirus, Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
55 CHRNA2 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
56 CHRNA3 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
57 CHRNA4 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
58 CHRNA4 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D08669 Varenicline [3] 6, 18, 53
59 CHRNA5 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
60 CHRNA7 [3] Neuroactive ligand-receptor interaction, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
61 CHRNB1 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
62 CHRNB2 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
63 CHRNB2 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D08669 Varenicline [3] 6, 18, 53
64 CHRNB3 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
65 CHRNB4 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
66 CHRND [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
67 CHRNE [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
68 CHRNG [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
69 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D00306 Dronabinol [8] 2, 8, 13, 36, 46, 96, 271, 298
70 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D05099 Nabilone [3] 6, 13, 127
71 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D05731 Rimonabant [1] 193
72 CNR1 [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol [20] 2, 6, 8, 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
73 CNR2 [1] Neuroactive ligand-receptor interaction D00306 Dronabinol [8] 2, 8, 13, 36, 46, 96, 271, 298
74 CNR2 [1] Neuroactive ligand-receptor interaction D05099 Nabilone [3] 6, 13, 127
75 CNR2 [1] Neuroactive ligand-receptor interaction D10915 Cannabidiol [20] 2, 6, 8, 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
76 CNR2 [1] Neuroactive ligand-receptor interaction D11312 Ajulemic acid [3] 50, 51, 299
77 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D00045 Adenosine [3] 13, 58, 65
78 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D00227 Aminophylline [1] 63
79 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D00371 Theophylline [2] 236, 299
80 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
81 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
82 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D02769 Adenosine phosphate [1] 46
83 ADORA1 [4] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion D06103 Theophylline [2] 236, 299
84 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D00045 Adenosine [3] 13, 58, 65
85 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D00528 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
86 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D01453 Caffeine [8] 2, 6, 21, 46, 78, 96, 97, 265
87 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D02769 Adenosine phosphate [1] 46
88 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D04641 Istradefylline [1] 6
89 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D05711 Regadenoson [1] 58
90 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D09717 Preladenant [1] 6
91 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D10174 Tozadenant [1] 6
92 ADORA2A [4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease D12568 Regadenoson [1] 58
93 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00045 Adenosine [3] 13, 58, 65
94 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00227 Aminophylline [1] 63
95 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00371 Theophylline [2] 236, 299
96 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D02769 Adenosine phosphate [1] 46
97 ADORA2B [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06103 Theophylline [2] 236, 299
98 CRHR1 [1] Neuroactive ligand-receptor interaction D03592 Corticorelin ovine triflutate [1] 75
99 CRHR1 [1] Neuroactive ligand-receptor interaction D03905 Corticorelin [1] 75
100 CRHR2 [1] Neuroactive ligand-receptor interaction D03592 Corticorelin ovine triflutate [1] 75
101 CRHR2 [1] Neuroactive ligand-receptor interaction D03905 Corticorelin [1] 75
102 ADORA3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00045 Adenosine [3] 13, 58, 65
103 ADORA3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02769 Adenosine phosphate [1] 46
104 ADORA3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10971 Piclidenoson [1] 46
105 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [2] 22, 296
106 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
107 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
108 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [4] 57, 86, 113, 210
109 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
110 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
111 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
112 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
113 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
114 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [1] 280
115 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
116 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
117 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
118 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin [1] 13
119 ADRA1D [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
120 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [2] 22, 296
121 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
122 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
123 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [4] 57, 86, 113, 210
124 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
125 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
126 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
127 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
128 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
129 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [1] 280
130 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
131 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
132 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
133 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin [1] 13
134 ADRA1B [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
135 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [2] 22, 296
136 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
137 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
138 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [4] 57, 86, 113, 210
139 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
140 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
141 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin [2] 6, 13
142 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
143 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
144 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin [1] 13
145 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
146 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [1] 280
147 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
148 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
149 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
150 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08560 Tamsulosin [1] 13
151 ADRA1A [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
152 ADRA2A [1] Neuroactive ligand-receptor interaction D00076 Norepinephrine [2] 22, 296
153 ADRA2A [1] Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
154 ADRA2A [1] Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
155 ADRA2A [1] Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
156 ADRA2A [1] Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
157 ADRA2A [1] Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
158 ADRA2A [1] Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [14] 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
159 ADRA2A [1] Neuroactive ligand-receptor interaction D00560 Pimozide [1] 2
160 ADRA2A [1] Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
161 ADRA2A [1] Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
162 ADRA2A [1] Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
163 ADRA2A [1] Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
164 ADRA2A [1] Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
165 ADRA2A [1] Neuroactive ligand-receptor interaction D08031 Guanfacine [1] 193
166 ADRA2A [1] Neuroactive ligand-receptor interaction D08207 Methylergometrine [1] 280
167 ADRA2A [1] Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
168 ADRA2A [1] Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
169 ADRA2A [1] Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
170 ADRA2A [1] Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
171 ADRA2B [1] Neuroactive ligand-receptor interaction D00076 Norepinephrine [2] 22, 296
172 ADRA2B [1] Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
173 ADRA2B [1] Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
174 ADRA2B [1] Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
175 ADRA2B [1] Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
176 ADRA2B [1] Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
177 ADRA2B [1] Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [14] 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
178 ADRA2B [1] Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
179 ADRA2B [1] Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
180 ADRA2B [1] Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
181 ADRA2B [1] Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
182 ADRA2B [1] Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
183 ADRA2B [1] Neuroactive ligand-receptor interaction D08207 Methylergometrine [1] 280
184 ADRA2B [1] Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
185 ADRA2B [1] Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
186 ADRA2B [1] Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
187 ADRA2B [1] Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
188 ADRA2C [1] Neuroactive ligand-receptor interaction D00076 Norepinephrine [2] 22, 296
189 ADRA2C [1] Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
190 ADRA2C [1] Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
191 ADRA2C [1] Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
192 ADRA2C [1] Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
193 ADRA2C [1] Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
194 ADRA2C [1] Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [14] 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280
195 ADRA2C [1] Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
196 ADRA2C [1] Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
197 ADRA2C [1] Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
198 ADRA2C [1] Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
199 ADRA2C [1] Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
200 ADRA2C [1] Neuroactive ligand-receptor interaction D08207 Methylergometrine [1] 280
201 ADRA2C [1] Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
202 ADRA2C [1] Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
203 ADRA2C [1] Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
204 ADRA2C [1] Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
205 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00076 Norepinephrine [2] 22, 296
206 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
207 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00124 Ephedrine [1] 11
208 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00235 Atenolol [1] 167
209 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00255 Carvedilol [4] 57, 86, 113, 210
210 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00378 Timolol [2] 157, 227
211 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00432 Nadolol [1] 6
212 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
213 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02342 Bisoprolol [4] 58, 67, 86, 113
214 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02349 Dipivefrin [1] 6
215 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02358 Metoprolol [6] 17, 57, 58, 113, 193, 226
216 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02910 Amiodarone [2] 28, 127
217 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D03879 Dobutamine [4] 57, 58, 86, 215
218 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05127 Nebivolol [4] 17, 85, 113, 167
219 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D07660 Celiprolol [1] 168
220 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D07916 Esmolol [1] 58
221 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
222 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08449 Pseudoephedrine [1] 17
223 ADRB1 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08600 Timolol [2] 157, 227
224 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00076 Norepinephrine [2] 22, 296
225 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
226 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00124 Ephedrine [1] 11
227 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00255 Carvedilol [4] 57, 86, 113, 210
228 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00378 Timolol [2] 157, 227
229 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00432 Nadolol [1] 6
230 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
231 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02147 Salbutamol [12] 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299
232 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02151 Tulobuterol [1] 6
233 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02349 Dipivefrin [1] 6
234 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D05792 Salmeterol [1] 299
235 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D07713 Clenbuterol [5] 1, 2, 6, 13, 256
236 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D07990 Formoterol [3] 85, 228, 299
237 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08092 Isoxsuprine [1] 13
238 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08124 Levosalbutamol [1] 49
239 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
240 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08449 Pseudoephedrine [1] 17
241 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08570 Terbutaline [1] 118
242 ADRB2 [4] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08600 Timolol [2] 157, 227
243 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00076 Norepinephrine [2] 22, 296
244 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
245 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D00124 Ephedrine [1] 11
246 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
247 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D02349 Dipivefrin [1] 6
248 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08443 Propranolol [6] 6, 158, 167, 227, 278, 296
249 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D08449 Pseudoephedrine [1] 17
250 ADRB3 [5] Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion D09535 Mirabegron [4] 6, 13, 53, 226
251 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
252 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D01044 Flupentixol [1] 97
253 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D07460 Apomorphine [3] 5, 6, 7
254 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D07870 Dopamine [4] 6, 7, 74, 299
255 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D08339 Pergolide [1] 6
256 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D09886 Dexpramipexole [1] 2
257 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D11431 Tavapadon [1] 6
258 DRD1 [2] Neuroactive ligand-receptor interaction, Parkinson disease D11839 Foslevodopa [1] 6
259 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
260 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00136 Haloperidol [1] 8
261 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00270 Chlorpromazine [1] 254
262 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00426 Risperidone [5] 8, 156, 179, 187, 206
263 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00454 Olanzapine [2] 2, 8
264 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00560 Pimozide [1] 2
265 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00726 Metoclopramide [2] 46, 51
266 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D00987 Cabergoline [3] 6, 74, 75
267 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01044 Flupentixol [1] 97
268 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01164 Aripiprazole [2] 6, 206
269 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01226 Sulpiride [2] 6, 70
270 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01348 Terguride [2] 51, 86
271 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01448 Trifluoperazine [2] 283, 284
272 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D01745 Domperidone [5] 6, 13, 17, 51, 230
273 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D02666 Iloperidone [1] 6
274 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D03165 Bromocriptine [2] 6, 74
275 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D05575 Pramipexole [3] 2, 6, 20
276 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D05768 Rotigotine [1] 6
277 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07305 Piribedil [1] 6
278 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07309 Melperone [1] 6
279 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07460 Apomorphine [3] 5, 6, 7
280 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07593 Buspirone [2] 6, 51
281 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07868 Domperidone [5] 6, 13, 17, 51, 230
282 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D07870 Dopamine [4] 6, 7, 74, 299
283 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08132 Lisuride [2] 6, 86
284 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08339 Pergolide [1] 6
285 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08456 Quetiapine [2] 6, 13
286 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08489 Ropinirole [4] 2, 6, 74, 309
287 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08590 Tiapride [1] 8
288 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D08636 Trifluoperazine [2] 283, 284
289 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D09397 Pardoprunox [1] 6
290 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D09886 Dexpramipexole [1] 2
291 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D09953 Pridopidine [3] 2, 6, 8
292 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D09997 Cariprazine [1] 21
293 DRD2 [3] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease D11839 Foslevodopa [1] 6
294 DRD3 [1] Neuroactive ligand-receptor interaction D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
295 DRD3 [1] Neuroactive ligand-receptor interaction D00454 Olanzapine [2] 2, 8
296 DRD3 [1] Neuroactive ligand-receptor interaction D01164 Aripiprazole [2] 6, 206
297 DRD3 [1] Neuroactive ligand-receptor interaction D05575 Pramipexole [3] 2, 6, 20
298 DRD3 [1] Neuroactive ligand-receptor interaction D07305 Piribedil [1] 6
299 DRD3 [1] Neuroactive ligand-receptor interaction D07870 Dopamine [4] 6, 7, 74, 299
300 DRD3 [1] Neuroactive ligand-receptor interaction D08132 Lisuride [2] 6, 86
301 DRD3 [1] Neuroactive ligand-receptor interaction D08489 Ropinirole [4] 2, 6, 74, 309
302 DRD3 [1] Neuroactive ligand-receptor interaction D09397 Pardoprunox [1] 6
303 DRD3 [1] Neuroactive ligand-receptor interaction D09886 Dexpramipexole [1] 2
304 DRD3 [1] Neuroactive ligand-receptor interaction D11839 Foslevodopa [1] 6
305 DRD4 [1] Neuroactive ligand-receptor interaction D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
306 DRD4 [1] Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
307 DRD4 [1] Neuroactive ligand-receptor interaction D00454 Olanzapine [2] 2, 8
308 DRD4 [1] Neuroactive ligand-receptor interaction D05575 Pramipexole [3] 2, 6, 20
309 DRD4 [1] Neuroactive ligand-receptor interaction D07870 Dopamine [4] 6, 7, 74, 299
310 DRD4 [1] Neuroactive ligand-receptor interaction D08132 Lisuride [2] 6, 86
311 DRD4 [1] Neuroactive ligand-receptor interaction D08489 Ropinirole [4] 2, 6, 74, 309
312 DRD4 [1] Neuroactive ligand-receptor interaction D09886 Dexpramipexole [1] 2
313 DRD4 [1] Neuroactive ligand-receptor interaction D11839 Foslevodopa [1] 6
314 DRD5 [1] Neuroactive ligand-receptor interaction D00059 Levodopa [6] 6, 17, 90, 140, 164, 201
315 DRD5 [1] Neuroactive ligand-receptor interaction D07870 Dopamine [4] 6, 7, 74, 299
316 DRD5 [1] Neuroactive ligand-receptor interaction D09886 Dexpramipexole [1] 2
317 DRD5 [1] Neuroactive ligand-receptor interaction D11431 Tavapadon [1] 6
318 DRD5 [1] Neuroactive ligand-receptor interaction D11839 Foslevodopa [1] 6
319 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00150 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
320 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00400 Valsartan [7] 57, 58, 66, 75, 218, 222, 224
321 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00522 Candesartan [2] 58, 67
322 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00523 Irbesartan [4] 66, 167, 168, 222
323 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00626 Candesartan cilexetil [1] 67
324 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D00627 Telmisartan [2] 66, 67
325 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D02014 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
326 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D08146 Losartan [17] 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
327 AGTR1 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin-angiotensin system, Renin secretion, Pathways in cancer D11776 Sparsentan [3] 66, 218, 222
328 AGTR2 [2] Neuroactive ligand-receptor interaction, Renin-angiotensin system D00150 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
329 AGTR2 [2] Neuroactive ligand-receptor interaction, Renin-angiotensin system D02014 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
330 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10001 Fingolimod [3] 13, 14, 156
331 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10905 Amiselimod [1] 97
332 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
333 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
334 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11215 Ponesimod [1] 13
335 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11283 Cenerimod [1] 49
336 S1PR1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11460 Siponimod [2] 13, 50
337 S1PR3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10905 Amiselimod [1] 97
338 S1PR3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
339 S1PR3 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
340 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D01227 Bosentan [10] 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
341 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07077 Ambrisentan [7] 51, 84, 85, 86, 88, 210, 211
342 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07171 Sitaxentan [1] 86
343 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07538 Bosentan [10] 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
344 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07741 Zibotentan [1] 51
345 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D10135 Macitentan [5] 51, 85, 86, 88, 210
346 EDNRA [4] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D11776 Sparsentan [3] 66, 218, 222
347 EDNRB [3] Neuroactive ligand-receptor interaction, Relaxin signaling pathway, Pathways in cancer D01227 Bosentan [10] 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
348 EDNRB [3] Neuroactive ligand-receptor interaction, Relaxin signaling pathway, Pathways in cancer D07538 Bosentan [10] 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
349 EDNRB [3] Neuroactive ligand-receptor interaction, Relaxin signaling pathway, Pathways in cancer D10135 Macitentan [5] 51, 85, 86, 88, 210
350 F2 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation, Regulation of actin cytoskeleton, Pathogenic Escherichia coli infection, Pathways in cancer D06410 Thrombomodulin Alfa [1] 85
351 F2 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation, Regulation of actin cytoskeleton, Pathogenic Escherichia coli infection, Pathways in cancer D07144 Dabigatran etexilate [2] 51, 75
352 F2 [6] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation, Regulation of actin cytoskeleton, Pathogenic Escherichia coli infection, Pathways in cancer D09707 Dabigatran [5] 51, 75, 85, 91, 124
353 GABBR1 [2] Neuroactive ligand-receptor interaction, Taste transduction D00241 Baclofen [8] 2, 10, 13, 18, 65, 70, 149, 206
354 GABBR1 [2] Neuroactive ligand-receptor interaction, Taste transduction D08861 Arbaclofen Placarbil [1] 13
355 GABBR1 [2] Neuroactive ligand-receptor interaction, Taste transduction D09791 Arbaclofen [2] 13, 206
356 GABBR1 [2] Neuroactive ligand-receptor interaction, Taste transduction D12240 Valiloxybate [1] 6
357 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
358 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
359 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
360 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [1] 36
361 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
362 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00548 Etomidate [1] 6
363 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
364 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
365 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
366 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
367 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
368 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
369 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
370 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
371 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
372 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
373 GABRA1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
374 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
375 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
376 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
377 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [1] 36
378 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
379 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
380 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
381 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
382 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
383 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
384 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
385 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
386 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
387 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
388 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
389 GABRA2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
390 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
391 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
392 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
393 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [1] 36
394 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
395 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
396 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
397 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
398 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
399 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
400 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
401 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
402 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
403 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
404 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
405 GABRA3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
406 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
407 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
408 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
409 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [1] 36
410 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
411 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
412 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
413 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
414 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
415 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
416 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
417 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
418 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
419 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
420 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
421 GABRA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
422 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
423 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
424 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
425 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [1] 36
426 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
427 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
428 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
429 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
430 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
431 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
432 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
433 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
434 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
435 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
436 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
437 GABRA5 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
438 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00225 Alprazolam [2] 8, 75
439 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00280 Clonazepam [1] 6
440 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
441 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00365 Lorazepam [1] 36
442 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
443 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
444 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
445 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
446 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01253 Clobazam [2] 140, 144
447 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D01372 Zopiclone [1] 6
448 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
449 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04282 Gaboxadol [2] 201, 206
450 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
451 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
452 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
453 GABRA6 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Taste transduction, Nicotine addiction D11149 Brexanolone [1] 205
454 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00225 Alprazolam [2] 8, 75
455 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00280 Clonazepam [1] 6
456 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
457 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00365 Lorazepam [1] 36
458 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
459 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
460 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
461 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
462 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01253 Clobazam [2] 140, 144
463 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01372 Zopiclone [1] 6
464 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
465 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04282 Gaboxadol [2] 201, 206
466 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
467 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
468 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
469 GABRB1 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D11149 Brexanolone [1] 205
470 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00225 Alprazolam [2] 8, 75
471 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00280 Clonazepam [1] 6
472 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
473 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00365 Lorazepam [1] 36
474 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
475 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
476 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
477 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
478 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01253 Clobazam [2] 140, 144
479 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01372 Zopiclone [1] 6
480 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
481 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04282 Gaboxadol [2] 201, 206
482 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
483 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
484 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
485 GABRB2 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D11149 Brexanolone [1] 205
486 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00225 Alprazolam [2] 8, 75
487 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00280 Clonazepam [1] 6
488 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
489 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00365 Lorazepam [1] 36
490 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
491 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
492 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
493 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
494 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01253 Clobazam [2] 140, 144
495 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D01372 Zopiclone [1] 6
496 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
497 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04282 Gaboxadol [2] 201, 206
498 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
499 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
500 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
501 GABRB3 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, Nicotine addiction D11149 Brexanolone [1] 205
502 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
503 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
504 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
505 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [1] 36
506 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
507 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
508 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
509 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
510 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
511 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
512 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
513 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
514 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
515 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
516 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
517 GABRD [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
518 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
519 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
520 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
521 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [1] 36
522 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
523 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
524 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
525 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
526 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
527 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
528 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
529 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
530 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
531 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
532 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
533 GABRE [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
534 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
535 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
536 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
537 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [1] 36
538 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
539 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
540 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
541 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
542 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
543 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
544 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
545 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
546 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
547 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
548 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
549 GABRG1 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
550 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
551 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
552 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
553 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [1] 36
554 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
555 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
556 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
557 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
558 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
559 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
560 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
561 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
562 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
563 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
564 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
565 GABRG2 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
566 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
567 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
568 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
569 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [1] 36
570 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
571 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
572 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
573 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
574 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
575 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
576 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
577 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
578 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
579 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
580 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
581 GABRG3 [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
582 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
583 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
584 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
585 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [1] 36
586 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
587 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
588 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
589 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
590 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
591 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
592 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
593 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
594 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
595 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
596 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
597 GABRP [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
598 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D03297 Mecasermin [6] 65, 78, 96, 168, 265, 299
599 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D05394 Pegvisomant [2] 78, 265
600 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D11193 Somavaratan [1] 78
601 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D11194 Somapacitan [2] 78, 195
602 GHR [2] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway D11486 Lonapegsomatropin [1] 78
603 GHRHR [1] Neuroactive ligand-receptor interaction D06655 Tesamorelin [2] 78, 265
604 GHRHR [1] Neuroactive ligand-receptor interaction D08523 Somatorelin [2] 13, 78
605 GHSR [1] Neuroactive ligand-receptor interaction D10563 Macimorelin [1] 78
606 GIPR [1] Neuroactive ligand-receptor interaction D11360 Tirzepatide [1] 233
607 GLP1R [1] Neuroactive ligand-receptor interaction D04121 Exenatide [6] 6, 17, 72, 78, 193, 233
608 GLP1R [1] Neuroactive ligand-receptor interaction D06404 Liraglutide [3] 6, 75, 193
609 GLP1R [1] Neuroactive ligand-receptor interaction D09729 Lixisenatide [1] 6
610 GLP1R [1] Neuroactive ligand-receptor interaction D09889 Dulaglutide [2] 13, 299
611 GLP1R [1] Neuroactive ligand-receptor interaction D10025 Semaglutide [1] 6
612 GLP1R [1] Neuroactive ligand-receptor interaction D11360 Tirzepatide [1] 233
613 GNRHR [1] Neuroactive ligand-receptor interaction D02369 Histrelin [1] 76
614 GNRHR [1] Neuroactive ligand-receptor interaction D04405 Goserelin [1] 1
615 GNRHR [1] Neuroactive ligand-receptor interaction D06247 Triptorelin [2] 49, 76
616 GNRHR [1] Neuroactive ligand-receptor interaction D07665 Cetrorelix [1] 46
617 GNRHR [1] Neuroactive ligand-receptor interaction D08027 Gonadorelin [1] 76
618 GRIA1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
619 GRIA1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
620 GRIA1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
621 GRIA1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
622 GRIA2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
623 GRIA2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
624 GRIA2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
625 GRIA2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
626 GRIA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
627 GRIA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
628 GRIA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
629 GRIA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
630 GRIA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
631 GRIA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
632 GRIA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
633 GRIA4 [4] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
634 GRIK1 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
635 GRIK1 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
636 GRIK2 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
637 GRIK2 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
638 GRIK3 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
639 GRIK3 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
640 GRIK4 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
641 GRIK4 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
642 GRIK5 [1] Neuroactive ligand-receptor interaction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
643 GRIK5 [1] Neuroactive ligand-receptor interaction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
644 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
645 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
646 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
647 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
648 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
649 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
650 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
651 GRIN1 [7] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
652 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
653 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
654 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
655 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
656 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
657 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
658 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
659 GRIN2A [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
660 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
661 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
662 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
663 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
664 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
665 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
666 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
667 GRIN2B [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
668 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
669 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
670 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
671 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
672 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
673 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
674 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
675 GRIN2C [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
676 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
677 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
678 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
679 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
680 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
681 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
682 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
683 GRIN2D [5] Neuroactive ligand-receptor interaction, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
684 NR3C1 [1] Neuroactive ligand-receptor interaction D00088 Hydrocortisone [10] 6, 41, 46, 53, 75, 78, 81, 83, 97, 299
685 NR3C1 [1] Neuroactive ligand-receptor interaction D00165 Hydrocortisone acetate [1] 97
686 NR3C1 [1] Neuroactive ligand-receptor interaction D00244 Betamethasone [8] 2, 28, 46, 65, 83, 90, 96, 235
687 NR3C1 [1] Neuroactive ligand-receptor interaction D00246 Budesonide [9] 66, 93, 94, 95, 96, 97, 98, 228, 299
688 NR3C1 [1] Neuroactive ligand-receptor interaction D00292 Dexamethasone [22] 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299
689 NR3C1 [1] Neuroactive ligand-receptor interaction D00385 Triamcinolone [11] 35, 46, 53, 56, 70, 90, 96, 107, 162, 226, 298
690 NR3C1 [1] Neuroactive ligand-receptor interaction D00407 Methylprednisolone [46] 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296
691 NR3C1 [1] Neuroactive ligand-receptor interaction D00472 Prednisolone [42] 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300
692 NR3C1 [1] Neuroactive ligand-receptor interaction D00473 Prednisone [45] 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331
693 NR3C1 [1] Neuroactive ligand-receptor interaction D00585 Mifepristone [1] 75
694 NR3C1 [1] Neuroactive ligand-receptor interaction D00689 Beclomethasone dipropionate [3] 85, 97, 98
695 NR3C1 [1] Neuroactive ligand-receptor interaction D00690 Mometasone furoate [2] 98, 162
696 NR3C1 [1] Neuroactive ligand-receptor interaction D00973 Cortisone acetate [1] 81
697 NR3C1 [1] Neuroactive ligand-receptor interaction D00976 Hydrocortisone cypionate [3] 6, 81, 83
698 NR3C1 [1] Neuroactive ligand-receptor interaction D00980 Prednisolone acetate [1] 222
699 NR3C1 [1] Neuroactive ligand-receptor interaction D01272 Clobetasol propionate [2] 46, 162
700 NR3C1 [1] Neuroactive ligand-receptor interaction D01442 Hydrocortisone succinate [3] 6, 81, 83
701 NR3C1 [1] Neuroactive ligand-receptor interaction D01703 Ciclesonide [1] 84
702 NR3C1 [1] Neuroactive ligand-receptor interaction D01708 Fluticasone propionate [2] 98, 228
703 NR3C1 [1] Neuroactive ligand-receptor interaction D01825 Fluocinolone acetonide [1] 90
704 NR3C1 [1] Neuroactive ligand-receptor interaction D03671 Deflazacort [2] 30, 113
705 NR3C1 [1] Neuroactive ligand-receptor interaction D05000 Methylprednisolone hemisuccinate [7] 13, 49, 50, 51, 53, 97, 211
706 NR3C1 [1] Neuroactive ligand-receptor interaction D07202 Halometasone [1] 162
707 NR3C1 [1] Neuroactive ligand-receptor interaction D07715 Clobetasol [4] 39, 46, 51, 162
708 NR3C1 [1] Neuroactive ligand-receptor interaction D07749 Cortisone [1] 81
709 NR3C1 [1] Neuroactive ligand-receptor interaction D07981 Fluticasone [3] 98, 228, 299
710 NR3C1 [1] Neuroactive ligand-receptor interaction D08227 Mometasone [2] 98, 162
711 NR3C1 [1] Neuroactive ligand-receptor interaction D08416 Prednisone acetate [6] 35, 41, 46, 49, 162, 224
712 NR3C1 [1] Neuroactive ligand-receptor interaction D11000 Vamorolone [2] 97, 113
713 NR3C1 [1] Neuroactive ligand-receptor interaction D11336 Relacorilant [1] 75
714 HCRTR1 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [3] 5, 6, 13
715 HCRTR2 [1] Neuroactive ligand-receptor interaction D10082 Suvorexant [3] 5, 6, 13
716 HRH1 [1] Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
717 HRH1 [1] Neuroactive ligand-receptor interaction D00300 Diphenhydramine [8] 11, 13, 49, 51, 70, 86, 222, 256
718 HRH1 [1] Neuroactive ligand-receptor interaction D00364 Loratadine [4] 13, 46, 89, 98
719 HRH1 [1] Neuroactive ligand-receptor interaction D00454 Olanzapine [2] 2, 8
720 HRH1 [1] Neuroactive ligand-receptor interaction D00494 Promethazine [1] 96
721 HRH1 [1] Neuroactive ligand-receptor interaction D03535 Clemastine [1] 13
722 HRH1 [1] Neuroactive ligand-receptor interaction D03693 Desloratadine [1] 13
723 HRH1 [1] Neuroactive ligand-receptor interaction D07398 Chlorpheniramine [1] 14
724 HRH1 [1] Neuroactive ligand-receptor interaction D07402 Levocetirizine [1] 61
725 HRH1 [1] Neuroactive ligand-receptor interaction D07407 Rupatadine [1] 46
726 HRH1 [1] Neuroactive ligand-receptor interaction D07662 Cetirizine [4] 13, 28, 35, 300
727 HRH1 [1] Neuroactive ligand-receptor interaction D07803 Dexchlorpheniramine [2] 13, 49
728 HRH1 [1] Neuroactive ligand-receptor interaction D07875 Doxepin [1] 6
729 HRH1 [1] Neuroactive ligand-receptor interaction D07958 Fexofenadine [2] 13, 46
730 HRH2 [1] Neuroactive ligand-receptor interaction D00295 Cimetidine [2] 2, 254
731 HRH2 [1] Neuroactive ligand-receptor interaction D00318 Famotidine [6] 6, 46, 61, 86, 98, 107
732 HRH2 [1] Neuroactive ligand-receptor interaction D00422 Ranitidine [2] 13, 65
733 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D01164 Aripiprazole [2] 6, 206
734 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D07593 Buspirone [2] 6, 51
735 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D09397 Pardoprunox [1] 6
736 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D09997 Cariprazine [1] 21
737 HTR1A [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D10184 Vortioxetine [1] 6
738 HTR1B [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00415 Zolmitriptan [1] 6
739 HTR1D [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D00415 Zolmitriptan [1] 6
740 HTR1D [3] Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction D07945 Fenfluramine [4] 140, 144, 145, 149
741 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00270 Chlorpromazine [1] 254
742 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00274 Cisapride [1] 13
743 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00283 Clozapine [1] 6
744 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00426 Risperidone [5] 8, 156, 179, 187, 206
745 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
746 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D01164 Aripiprazole [2] 6, 206
747 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02092 Cisapride [1] 13
748 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02666 Iloperidone [1] 6
749 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D07945 Fenfluramine [4] 140, 144, 145, 149
750 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08456 Quetiapine [2] 6, 13
751 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08626 Trazodone [1] 2
752 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D09645 Nelotanserin [1] 6
753 HTR2A [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D09997 Cariprazine [1] 21
754 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00270 Chlorpromazine [1] 254
755 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
756 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02666 Iloperidone [1] 6
757 HTR2B [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08626 Trazodone [1] 2
758 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00270 Chlorpromazine [1] 254
759 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00283 Clozapine [1] 6
760 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
761 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02578 Agomelatine [1] 6
762 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02666 Iloperidone [1] 6
763 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D07945 Fenfluramine [4] 140, 144, 145, 149
764 HTR2C [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08626 Trazodone [1] 2
765 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00274 Cisapride [1] 13
766 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D02092 Cisapride [1] 13
767 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D08236 Mosapride [1] 96
768 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D09205 Prucalopride [3] 13, 51, 96
769 HTR4 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D09693 Velusetrag [1] 99
770 HTR6 [2] Neuroactive ligand-receptor interaction, Serotonergic synapse D00454 Olanzapine [2] 2, 8
771 LEPR [2] Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease D05014 Metreleptin [1] 265
772 MC1R [1] Neuroactive ligand-receptor interaction D10511 Afamelanotide [3] 159, 161, 254
773 MC2R [1] Neuroactive ligand-receptor interaction D00146 Corticotropin [12] 2, 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222
774 MC2R [1] Neuroactive ligand-receptor interaction D00284 Tetracosactide [5] 78, 83, 113, 145, 222
775 MC4R [1] Neuroactive ligand-receptor interaction D11927 Setmelanotide [2] 202, 265
776 MTNR1A [1] Neuroactive ligand-receptor interaction D02578 Agomelatine [1] 6
777 MTNR1A [1] Neuroactive ligand-receptor interaction D02689 Ramelteon [3] 6, 8, 46
778 MTNR1A [1] Neuroactive ligand-receptor interaction D08170 Melatonin [12] 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202
779 MTNR1A [1] Neuroactive ligand-receptor interaction D09388 Tasimelteon [1] 202
780 MTNR1B [1] Neuroactive ligand-receptor interaction D02578 Agomelatine [1] 6
781 MTNR1B [1] Neuroactive ligand-receptor interaction D02689 Ramelteon [3] 6, 8, 46
782 MTNR1B [1] Neuroactive ligand-receptor interaction D08170 Melatonin [12] 6, 8, 13, 37, 46, 49, 72, 78, 90, 97, 145, 202
783 MTNR1B [1] Neuroactive ligand-receptor interaction D09388 Tasimelteon [1] 202
784 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
785 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
786 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone [5] 6, 13, 70, 226, 298
787 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08144 Loperamide [2] 13, 97
788 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08246 Nalbuphine [1] 85
789 OPRD1 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
790 OPRK1 [1] Neuroactive ligand-receptor interaction D00838 Dezocine [1] 46
791 OPRK1 [1] Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
792 OPRK1 [1] Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
793 OPRK1 [1] Neuroactive ligand-receptor interaction D05312 Oxycodone [5] 6, 13, 70, 226, 298
794 OPRK1 [1] Neuroactive ligand-receptor interaction D07132 Buprenorphine [2] 46, 70
795 OPRK1 [1] Neuroactive ligand-receptor interaction D08144 Loperamide [2] 13, 97
796 OPRK1 [1] Neuroactive ligand-receptor interaction D08246 Nalbuphine [1] 85
797 OPRK1 [1] Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
798 OPRK1 [1] Neuroactive ligand-receptor interaction D08639 Trimebutine [1] 51
799 OPRM1 [1] Neuroactive ligand-receptor interaction D00320 Fentanyl [3] 46, 70, 215
800 OPRM1 [1] Neuroactive ligand-receptor interaction D00838 Dezocine [1] 46
801 OPRM1 [1] Neuroactive ligand-receptor interaction D05111 Nalmefene [1] 6
802 OPRM1 [1] Neuroactive ligand-receptor interaction D05113 Naltrexone [13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
803 OPRM1 [1] Neuroactive ligand-receptor interaction D05312 Oxycodone [5] 6, 13, 70, 226, 298
804 OPRM1 [1] Neuroactive ligand-receptor interaction D05938 Sufentanil [2] 70, 280
805 OPRM1 [1] Neuroactive ligand-receptor interaction D07132 Buprenorphine [2] 46, 70
806 OPRM1 [1] Neuroactive ligand-receptor interaction D07831 Dihydrocodeine [1] 310
807 OPRM1 [1] Neuroactive ligand-receptor interaction D08047 Hydromorphone [1] 70
808 OPRM1 [1] Neuroactive ligand-receptor interaction D08144 Loperamide [2] 13, 97
809 OPRM1 [1] Neuroactive ligand-receptor interaction D08233 Morphine [5] 36, 46, 70, 85, 86
810 OPRM1 [1] Neuroactive ligand-receptor interaction D08246 Nalbuphine [1] 85
811 OPRM1 [1] Neuroactive ligand-receptor interaction D08249 Naloxone [2] 6, 226
812 OPRM1 [1] Neuroactive ligand-receptor interaction D08323 Oxymorphone [1] 70
813 OPRM1 [1] Neuroactive ligand-receptor interaction D08473 Remifentanil [2] 6, 70
814 OPRM1 [1] Neuroactive ligand-receptor interaction D08623 Tramadol [5] 46, 70, 78, 226, 271
815 OPRM1 [1] Neuroactive ligand-receptor interaction D08639 Trimebutine [1] 51
816 OXTR [2] Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D00089 Oxytocin [7] 6, 72, 127, 168, 193, 206, 226
817 OXTR [2] Neuroactive ligand-receptor interaction, Oxytocin signaling pathway D03008 Atosiban [1] 118
818 P2RX3 [2] Neuroactive ligand-receptor interaction, Taste transduction D11349 Gefapixant [2] 85, 226
819 PLG [2] Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D00160 Aminocaproic acid [1] 70
820 PLG [2] Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D01136 Tranexamic acid [7] 46, 70, 215, 227, 274, 288, 299
821 S1PR5 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10905 Amiselimod [1] 97
822 S1PR5 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
823 S1PR5 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
824 S1PR5 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11460 Siponimod [2] 13, 50
825 AVPR1A [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin [1] 210
826 AVPR1A [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin [1] 299
827 AVPR1A [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D07748 Conivaptan [1] 86
828 AVPR1B [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin [1] 210
829 AVPR1B [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin [1] 299
830 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00101 Vasopressin [1] 210
831 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00291 Desmopressin [6] 6, 64, 72, 75, 225, 288
832 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D01213 Tolvaptan [4] 67, 72, 86, 225
833 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D04752 Lixivaptan [1] 67
834 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D06672 Terlipressin [1] 299
835 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D07748 Conivaptan [1] 86
836 CHRNA9 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
837 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00225 Alprazolam [2] 8, 75
838 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00280 Clonazepam [1] 6
839 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00293 Diazepam [3] 46, 155, 298
840 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00365 Lorazepam [1] 36
841 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
842 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00549 Propofol [9] 6, 21, 22, 34, 46, 70, 75, 98, 296
843 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00550 Midazolam [12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299
844 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
845 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01253 Clobazam [2] 140, 144
846 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D01372 Zopiclone [1] 6
847 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D02624 Eszopiclone [3] 6, 13, 46
848 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04282 Gaboxadol [2] 201, 206
849 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D04300 Ganaxolone [4] 145, 152, 158, 206
850 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D07784 Delorazepam [3] 6, 46, 97
851 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D08690 Zolpidem [3] 5, 6, 46
852 GABRQ [3] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Nicotine addiction D11149 Brexanolone [1] 205
853 PRL [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Prolactin signaling pathway D00987 Cabergoline [3] 6, 74, 75
854 PRL [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Prolactin signaling pathway D01348 Terguride [2] 51, 86
855 PRL [3] Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Prolactin signaling pathway D03165 Bromocriptine [2] 6, 74
856 CHRNA10 [1] Neuroactive ligand-receptor interaction D03365 Nicotine [3] 6, 13, 84
857 PTAFR [2] Neuroactive ligand-receptor interaction, Staphylococcus aureus infection D07407 Rupatadine [1] 46
858 PTGDR [1] Neuroactive ligand-receptor interaction D01128 Ramatroban [1] 13
859 PTGER1 [2] Neuroactive ligand-receptor interaction, Pathways in cancer D00180 Alprostadil [2] 51, 70
860 PTGER1 [2] Neuroactive ligand-receptor interaction, Pathways in cancer D02722 Limaprost [1] 70
861 PTGER2 [3] Neuroactive ligand-receptor interaction, Renin secretion, Pathways in cancer D00419 Misoprostol [3] 46, 70, 271
862 PTGER3 [3] Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Pathways in cancer D00419 Misoprostol [3] 46, 70, 271
863 PTGER4 [3] Neuroactive ligand-receptor interaction, Renin secretion, Pathways in cancer D00419 Misoprostol [3] 46, 70, 271
864 PTGFR [2] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction D06274 Tafluprost [1] 299
865 PTGFR [2] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction D08661 Unoprostone [1] 90
866 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D00106 Epoprostenol [1] 86
867 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D01385 Ibudilast [2] 2, 13
868 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D02720 Beraprost [1] 86
869 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D02721 Iloprost [4] 51, 84, 85, 86
870 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D06213 Treprostinil [6] 51, 84, 85, 86, 88, 210
871 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D09994 Selexipag [5] 51, 70, 84, 86, 88
872 PTGIR [3] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D10725 Ralinepag [1] 86
873 PTH1R [2] Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action D05364 Parathyroid hormone [4] 65, 70, 235, 326
874 PTH1R [2] Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action D06078 Teriparatide [7] 46, 65, 68, 70, 71, 235, 274
875 PTH2R [1] Neuroactive ligand-receptor interaction D05364 Parathyroid hormone [4] 65, 70, 235, 326
876 SSTR1 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
877 SSTR1 [1] Neuroactive ligand-receptor interaction D10147 Pasireotide [3] 67, 74, 75
878 SSTR2 [1] Neuroactive ligand-receptor interaction D00442 Octreotide [7] 67, 75, 84, 85, 89, 193, 227
879 SSTR2 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
880 SSTR2 [1] Neuroactive ligand-receptor interaction D10147 Pasireotide [3] 67, 74, 75
881 SSTR3 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
882 SSTR3 [1] Neuroactive ligand-receptor interaction D10147 Pasireotide [3] 67, 74, 75
883 SSTR4 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
884 SSTR5 [1] Neuroactive ligand-receptor interaction D07431 Somatostatin [2] 67, 78
885 SSTR5 [1] Neuroactive ligand-receptor interaction D10147 Pasireotide [3] 67, 74, 75
886 TACR1 [1] Neuroactive ligand-receptor interaction D09378 Serlopitant [1] 36
887 TACR1 [1] Neuroactive ligand-receptor interaction D09650 Orvepitant [1] 85
888 TBXA2R [2] Neuroactive ligand-receptor interaction, Platelet activation D01128 Ramatroban [1] 13
889 TBXA2R [2] Neuroactive ligand-receptor interaction, Platelet activation D01896 Cilostazol [3] 46, 51, 70
890 TBXA2R [2] Neuroactive ligand-receptor interaction, Platelet activation D04500 Ifetroban [2] 85, 113
891 THRA [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D07214 Tiratricol [2] 78, 139
892 THRA [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08125 Levothyroxine [5] 19, 49, 78, 80, 222
893 THRA [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08128 Liothyronine [4] 13, 78, 210, 212
894 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D07214 Tiratricol [2] 78, 139
895 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08125 Levothyroxine [5] 19, 49, 78, 80, 222
896 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08128 Liothyronine [4] 13, 78, 210, 212
897 THRB [2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D09381 Sobetirome [1] 20
898 C3 [9] Neuroactive ligand-receptor interaction, Phagosome, Neutrophil extracellular trap formation, Shigellosis, Pertussis, Staphylococcus aureus infection, Tuberculosis, Viral carcinogenesis, Systemic lupus erythematosus D11613 Pegcetacoplan [4] 2, 61, 62, 222
899 TRHR [1] Neuroactive ligand-receptor interaction D00176 Protirelin [1] 80
900 C5 [7] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D03940 Eculizumab [7] 11, 13, 14, 61, 62, 109, 222
901 C5 [7] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11054 Ravulizumab [7] 2, 11, 13, 50, 62, 66, 109
902 C5 [7] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11473 Nomacopan [3] 62, 109, 162
903 C5 [7] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11477 Pozelimab [2] 11, 62
904 C5 [7] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11696 Crovalimab [2] 62, 109
905 C5 [7] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D11838 Vilobelimab [3] 43, 44, 269
906 C5 [7] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Regulation of actin cytoskeleton, Prion disease, Pertussis, Staphylococcus aureus infection, Systemic lupus erythematosus D12357 Zilucoplan [3] 2, 11, 62
907 C5AR1 [3] Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Staphylococcus aureus infection D11093 Avacopan [3] 43, 44, 222
908 TRPV1 [1] Neuroactive ligand-receptor interaction D00250 Capsaicin [3] 6, 86, 226
909 CALCA [2] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D11055 Fremanezumab [2] 124, 226
910 S1PR4 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10905 Amiselimod [1] 97
911 S1PR4 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
912 S1PR4 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
913 CCKBR [1] Neuroactive ligand-receptor interaction D01818 Proglumide [1] 298
914 CHRNA6 [2] Neuroactive ligand-receptor interaction, Nicotine addiction D03365 Nicotine [3] 6, 13, 84
915 S1PR2 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10905 Amiselimod [1] 97
916 S1PR2 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10930 Etrasimod [3] 96, 97, 98
917 S1PR2 [2] Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod [3] 13, 96, 97
918 GLP2R [1] Neuroactive ligand-receptor interaction D06053 Teduglutide [1] 96
919 GABBR2 [2] Neuroactive ligand-receptor interaction, Taste transduction D00241 Baclofen [8] 2, 10, 13, 18, 65, 70, 149, 206
920 GABBR2 [2] Neuroactive ligand-receptor interaction, Taste transduction D08861 Arbaclofen Placarbil [1] 13
921 GABBR2 [2] Neuroactive ligand-receptor interaction, Taste transduction D09791 Arbaclofen [2] 13, 206
922 GABBR2 [2] Neuroactive ligand-receptor interaction, Taste transduction D12240 Valiloxybate [1] 6